Business Context and Reporting Period
Company: Inmed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 11, 2026
Reporting Period: Second quarter of fiscal year 2026, ended December 31, 2025.
Event: Regulation FD Disclosure regarding the reporting of financial results for the period mentioned above.
Key Financial Metrics
The provided filing text serves as a cover document for the disclosure of financial results but does not contain the specific numerical data. The following metrics are not present in the text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing states that detailed information is contained in Exhibit 99.1 (News release), which is not included in the provided input text.
Material Changes
The filing text does not provide specific data to compare against the prior comparable period. It only confirms that financial results for the second quarter of fiscal 2026 were reported on February 11, 2026.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that the Company reported financial results for the second quarter of fiscal 2026. No specific commentary, guidance, or outlook is included in the text of the 8-K itself.
Risks and Contingencies: No specific risks or contingencies are detailed in this document.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (News release dated February 11, 2026) for the actual financial figures, as they are not listed in the 8-K body.
- Verify the specific revenue, net loss, and cash burn rate for the quarter ended December 31, 2025.
- Check for any updated clinical trial milestones or regulatory developments mentioned in the full news release.
- Confirm the company's cash runway and liquidity position as of the quarter end.